Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model

Metabolic profiling of induced acute pancreatitis and pancreatic cancer progression in a mutant Kras mouse model

Untargeted Nuclear Magnetic Resonance (NMR) metabolomics of polar extracts from the pancreata of a caerulin-induced mouse model of pancreatitis (Pt) and of a transgenic mouse model of pancreatic cancer (PCa) were used to find metabolic markers of Pt and to characterize the metabolic changes accompan...

Full description

Bibliographic Details
Main Authors:	Tatiana J. Carneiro, Joana Pinto, Eva M. Serrao, António S. Barros, Kevin M. Brindle, Ana M. Gil
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Molecular Biosciences
Subjects:	pancreatitis pancreatic cancer PanIN pancreatic ductal adenocarcinoma KRAS metabolomics
Online Access:	https://www.frontiersin.org/articles/10.3389/fmolb.2022.937865/full

Similar Items

Zebrafish model of KRAS-initiated pancreatic cancer
by: Joon Tae Park, et al.
Published: (2018-11-01)

Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma
by: Timothy McGinnis, et al.
Published: (2020-09-01)

Acinar-to-Ductal Metaplasia (ADM): On the Road to Pancreatic Intraepithelial Neoplasia (PanIN) and Pancreatic Cancer
by: Louis Marstrand-Daucé, et al.
Published: (2023-06-01)

Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions
by: Geou-Yarh Liou, et al.
Published: (2016-03-01)

Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas
by: Sho Fujiwara, et al.
Published: (2019-04-01)

Kras as a key oncogene and therapeutic target in pancreatic cancer.
by: Meredith A Collins, et al.
Published: (2014-01-01)

Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma
by: Tsengelmaa Jamiyan, et al.
Published: (2020-06-01)

Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia
by: Friederike V. Opitz, et al.
Published: (2021-12-01)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
by: Prashanth Ashok Kumar, et al.
Published: (2023-06-01)

The Expression of Two Distinct Sets of Glycolytic Enzymes Reveals Differential Effects of Glycolytic Reprogramming on Pancreatic Ductal Tumorigenesis in Mice
by: Yannan Zhang, et al.
Published: (2023-11-01)

Clinical application of pancreatic juice‐derived small extracellular vesicles of pancreatic ductal adenocarcinoma
by: Koichiro Tsutsumi, et al.
Published: (2023-04-01)

Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer
by: Ruthger van Roey, et al.
Published: (2021-11-01)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
by: Yixuan Ma, et al.
Published: (2022-09-01)

PRDM14 is overexpressed in chronic pancreatitis prior to pancreatic cancer
by: Chiharu Moriya, et al.
Published: (2018-10-01)

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research
by: Sibylle Baechmann, et al.
Published: (2017-05-01)

Cyclooxygenase-2 Expression in Hamster and Human Pancreatic Neoplasia
by: Pamela L. Crowell, et al.
Published: (2006-06-01)

Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis
by: Shuai Tang, et al.
Published: (2023-11-01)

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial
by: Théo Legrand, et al.
Published: (2022-08-01)

A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice
by: Alexandre Quilbe, et al.
Published: (2023-11-01)

Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report
by: Seiji Nakahara, et al.
Published: (2023-08-01)

Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of <i>KRAS</i>
by: Sneha Vivekanandhan, et al.
Published: (2021-08-01)

Pancreatic tail cancer in the setting of pancreatitis with a review of the literature: A case report
by: Shinji Rho, et al.
Published: (2023-10-01)

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study
by: Fan Yang, et al.
Published: (2024-01-01)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
by: Albert Grinshpun, et al.
Published: (2019-01-01)

Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas—A Preliminary Study
by: Karolina Skubisz, et al.
Published: (2023-06-01)

Clinical features and images of malignant lymphoma localized in the pancreatic head to differentiate from pancreatic ductal adenocarcinoma: a case series study
by: Naohiro Kato, et al.
Published: (2023-05-01)

Differentiating benign from malignant pancreatic cysts on computed tomography
by: Rajesh Kumar Yadav, et al.
Published: (2020-01-01)

Single-PanIN-seq unveils that ARID1A deficiency promotes pancreatic tumorigenesis by attenuating KRAS-induced senescence
by: Shou Liu, et al.
Published: (2021-05-01)

Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study
by: Rui Zhao, et al.
Published: (2023-02-01)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
by: Chaobin He, et al.
Published: (2019-10-01)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
by: Jessica Allen, et al.
Published: (2020-10-01)

Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
by: Stephan J. Reshkin, et al.
Published: (2024-03-01)

Targeting Mutant <i>KRAS</i> in Pancreatic Cancer: Futile or Promising?
by: Friederike Inga Nollmann, et al.
Published: (2020-08-01)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
by: Josef Gillson, et al.
Published: (2020-05-01)

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study
by: Ritu R. Singh, et al.
Published: (2023-02-01)

<i>KRAS</i> Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
by: Meichen Gu, et al.
Published: (2021-05-01)

The TGF-β superfamily as potential therapeutic targets in pancreatic cancer
by: Rachel R. Tindall, et al.
Published: (2024-03-01)

Protective or Risk Factors for Postoperative Pancreatic Fistulas in Malignant Pathology
by: Alin Mihai Vasilescu, et al.
Published: (2021-11-01)

Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma
by: Sahar Ghassem-Zadeh, et al.
Published: (2017-06-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
by: Lukas M. Braun, et al.
Published: (2020-05-01)